Titre :

Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Auteur(s) :

Gauthier, Jordan [Auteur]
Chantepie, Sylvain [Auteur]
Bouabdallah, Krimo [Auteur]
Jost, Edgar [Auteur]
Nguyen, Stephanie [Auteur]
Gac, Anne-Claire [Auteur]
Damaj, Gandhi [Auteur]
Dulery, Remy [Auteur]
Michallet, Mauricette [Auteur]
Delage, Jeremy [Auteur]
Lewalle, Philippe [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Salles, Gilles [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Cornillon, Jerome [Auteur]

Titre de la revue :

Bulletin du cancer

Nom court de la revue :

Bull. Cancer

Numéro :

104

Pagination :

S121-S130

Date de publication :

2017

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially ...
Lire la suite >Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This paper specifically reports on our conclusions regarding indolent lymphomas, mainly follicular lymphoma and chronic lymphocytic leukemia.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Inserm

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:07:03Z